CD33 expression and its association with gemtuzumab ozogamicin response: Results from the randomized phase III children's oncology group trial AAML0531

Journal of Clinical Oncology

Volumn 34, Issue 7, 2016, Pages 747-755

  Pollard, Jessica A ^a,b   Loken, Michael ^c   Gerbing, Robert B ^e   Raimondi, Susana C ^g   Hirsch, Betsy A ^h   Aplenc, Richard ⁱ   Bernstein, Irwin D ^c,d   Gamis, Alan S ^j   Alonzo, Todd A ^e,f   Meshinchi, Soheil ^c,d  

^a Maine Children's Cancer Program Scarborough   (United States)

^b TUFTS UNIVERSITY   (United States)

^c Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j CHILDREN S MERCY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; CD33 PROTEIN, HUMAN; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DE NOVO ACUTE MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LEUKEMIA REMISSION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CLINICAL TRIAL; LEUKEMIA, MYELOID, ACUTE; METABOLISM; STEM CELL TRANSPLANTATION;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROSPECTIVE STUDIES; SIALIC ACID BINDING IG-LIKE LECTIN 3; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84964294715     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.6846     Document Type: Article

References (29)

1. Walter RB, AppelbaumFR, Estey EH, et al: Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119:6198-6208, 2012
2. Burnett AK, Hills RK, Milligan D, et al: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 29: 369-377, 2011
3. Delaunay J, Recher C, Pigneux A, et al: Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood 118:79, 2011
4. BurnettAK, Russell NH, Hills RK, et al: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924-3931, 2012
5. Castaigne S, Pautas C, Terré C, et al: Acute Leukemia French Association: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 379:1508-1516, 2012
6. Burnett AK, Hills RK, Hunter AE, et al; UK National Cancer Research Institute AML Working Group: The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: Results from the LRF AML14 and NCRI AML16 pick-awinner comparison. Leukemia 27:75-81, 2013
7. Laszlo GS, Estey EH, Walter RB: The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 28:143-153, 2014
8. Loke J, Khan JN, Wilson JS, et al: Mylotarg has potent anti-leukaemic effect: A systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 94:361-373, 2015
9. Hills RK, Castaigne S, Appelbaum FR, et al: Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patientswith acute myeloid leukaemia: Ameta-analysis of individual patient data fromrandomised controlled trials. Lancet Oncol 15:986-996, 2014
10. Thol F, Schlenk RF: Gemtuzumab ozogamicin in acute myeloid leukemia revisited. Expert Opin Biol Ther 14:1185-1195, 2014
11. Aplenc R, Alonzo TA, Gerbing RB, et al: Children's Oncology Group: Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: A report from the Children's Oncology Group. J Clin Oncol 26:2390-2395, 2008
12. Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 11:543-552, 2010
13. Cooper TM, Franklin J, Gerbing RB, et al: AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 118:761-769, 2012
14. Hasle H, Abrahamsson J, Forestier E, et al: Nordic Society of Paediatric Haematology and Oncology (NOPHO): Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: Results from NOPHO-AML 2004. Blood 120:978-984, 2012
15. O'Hear C, Inaba H, Pounds S, et al: Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 119:4036-4043, 2013
16. Gamis AS, Alonzo TA, Meshinchi S, et al: Gemtuzumab ozogamicin in children and adolescents with De novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 32:3021-3032, 2014
17. Pollard JA, Alonzo TA, Loken M, et al: Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 119:3705-3711, 2012
18. Walter RB, Alonzo TA, Gerbing RB, et al: High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. J Clin Oncol 28:2831-2838, 2010
19. Wells DA, Loken MR: Flow cytometric mean fluorescence intensity: The biophysics behind the number. Leuk Res 32:845-846, 2008
20. Loken MR, Alonzo TA, Pardo L, et al: Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with De novo acute myeloid leukemia: A report from Children's Oncology Group. Blood 120:1581-1588, 2012
21. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. Hoboken, NJ, John Wiley & Sons, 2002
22. Walter RB, Raden BW, Kamikura DM, et al: Influence of CD33 expression levels and ITIMdependent internalization on gemtuzumab ozogamicininduced cytotoxicity. Blood 105:1295-1302, 2005
23. Jager E, Van Der Velden VH, te Marvelde JG, et al: Targeted drug delivery by gemtuzumab ozogamicin: Mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS One 6:e24265, 2011
24. Jawad M, Seedhouse C, Mony U, et al: Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 24:74-80, 2010
25. Sievers EL, Appelbaum FR, Spielberger RT, et al: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678-3684, 1999
26. Sievers EL, Larson RA, Stadtmauer EA, et al: Mylotarg Study Group: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001
27. Walter RB, Gooley TA, Van Der Velden VH, et al: CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109:4168-4170, 2007
28. Petersdorf SH, Kopecky KJ, Slovak M, et al: A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121: 4854-4860, 2013
29. Kung Sutherland MS, Walter RB, Jeffrey SC, et al: SGN-CD33A: A novel CD33-targeting antibodydrug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122: 1455-1463, 2013